Stonegate Initiates Coverage on SES AI Corp. (SES)

Dallas, Texas--(Newsfile Corp. - June 2, 2026) - SES AI Corp. (NYSE: SES): Stonegate Capital Partners Initiates Coverage on SES AI Corp. (NYSE: SES). SES' 1Q26 update further shifts the story from EV battery development toward a commercialization model led by ESS, with drone cells, materials, and Molecular Universe adding clearer 2H26/2027 revenue paths. Revenue beat expectations, though Q1 benefited from ~$1.5M of 4Q25 revenue shifting into the period, so the better read is not run-rate extrapolation but improved mix, reaffirmed FY26 guidance, and better visibility into drone qualification, cost reductions, and AI-enabled product differentiation.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• SES is shifting from EV R&D toward commercialization, with ESS anchoring FY26 revenue and drone cells/materials adding clearer 2H26 and 2027 growth paths.

• 1Q26 revenue beat was helped by timing, but stronger gross margin, improved mix, and reaffirmed $30M-$35M guidance support execution credibility.

• Drone cells are the key upside variable, with NDAA-compliant samples shipping, defense interest building, and qualification potentially converting into fuller 2027 deliveries.

Click image above to view full announcement.

---

About Stonegate

Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking, equity research and capital raising for public and private companies.

Source: Stonegate, Inc.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/299818

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Thunder Mountain Gold Launches 2026 Drill Program at South Mountain
• Stifel Reiterates Buy Rating on Neurocrine Bio. (NBIX)
• ExxonMobil sets July 2026 date for Texas redomiciliation